Mo1952 A Highly Effective Anti-Vomiting Regimen Post Intragastric Balloon Implantation

Brooks, Jeffrey; Tsvang, Eduard; Ganon, Miriam; Ben-Ami, M.; Weiss, S; Hoffman, Meirav; Arnon, Roni

doi:10.1016/s0016-5085(16)32794-9

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aprepitant has been shown previously to control nausea and vomiting in individuals after surgery and those undergoing chemotherapy, and has been studied extensively in multiple randomized, controlled trials [21 -23]. In addition, its use with ondansetron has been reported to significantly decrease vomiting in individuals treated with another intragastric balloon [24]. In this study, intolerance was dramatically reduced with a combination of ondansetron and aprepitant.…”

Section: Discussionmentioning

confidence: 68%

Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study

Machytka

Gaur²,

Chuttani

et al. 2016

Endoscopy

View full text Add to dashboard Cite

Conventional gastric balloons for weight loss require endoscopy for placement and removal. The Elipse device is swallowed, resides in the stomach for 4 months, and is then expelled. The objectives of this study were to assess the safety of Elipse and to measure its effects on weight loss, metabolic parameters, and quality of life. Each participant swallowed one Elipse device, which was filled with 550 mL of filling fluid through a thin delivery catheter that was then removed. Weight was measured every 2 weeks, and metabolic parameters and quality of life were assessed at baseline and at trial exit. 34 patients, with a mean body mass index of 34.8 kg/m, were enrolled. All 34 patients successfully swallowed the Elipse device. All adverse events were either self-limiting or resolved with medication. All balloons were safely excreted. At 4 months, the mean percent total body weight loss was 10 %. Mean waist circumference was reduced by 8.4 cm. Improvements were also seen in hemoglobin A1c, triglycerides, low density lipoprotein, and blood pressure. At trial exit, quality of life measures had improved across all domains. These results demonstrate clinically significant weight loss with the Elipse, the first procedureless gastric balloon. The weight loss was similar to that seen in previous studies of endoscopically placed balloons. In addition, Elipse therapy led to improvements in waist circumference, several metabolic parameters, and overall quality of life.ClinicalTrials.gov identifier: NCT 02802007.

show abstract

Section: Discussionmentioning

confidence: 68%